Gerald Appel, MD, is a professor of clinical medicine, director of clinical nephrology, and director of the Glomerular Disease Center at Columbia University.

Luis Sanchez Russo, MD, is a nephrologist affiliating with Advent Health.

Associate Professor, Drexel University, Co-Director Autoimmune Kidney Disease Center, Allegheny Health Network

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

Rare Disease Day 2026: Kidney Diseases Enter Optimistic Therapeutic Era

On Rare Disease Day 2026, 4 clinicians share their insights and perspectives on the groundbreaking improvements in the rapidly evolving field of rare kidney diseases.

Despite persistent awareness gaps in rare kidney disease care, a wave of FDA approvals and phase 3 trial successes in 

 alongside updated 2025 KDIGO Practice Guidelines, has fueled growing clinician optimism about a rapidly advancing, disease-modifying treatment era.

Rare kidney diseases remain complex and underrecognized, leaving both patients and clinicians with challenges in early diagnosis, risk stratification, and long-term management. Yet recent scientific advances and regulatory approvals are beginning to reshape the therapeutic landscape.

Momentum in rare kidney disease care has accelerated with multiple FDA approvals supported by pivotal clinical trial data. In IgAN, 

demonstrated significant reductions in proteinuria and preservation of kidney function in the NefIgArd trial, while 

, a dual endothelin-angiotensin receptor antagonist, showed positive outcomes in the PROTECT study. The addition of 

, an endothelin A receptor antagonist, further underscores the diversification of therapeutic strategies in IgAN, with the ALIGN Phase III trial demonstrating clinically meaningful reductions in proteinuria, a key surrogate for slowing disease progression. Iptacopan, a factor B inhibitor targeting the alternative complement pathway, reported encouraging efficacy in the APPLAUSE-IgAN trial, highlighting a precision-based approach to treatment.

In C3G, iptacopan also showed promising results in the 

, alongside other complement-targeted therapies such as 

 and danicopan, reflecting growing opportunities for disease modification in a previously limited treatment space.

These advances are complemented by the updated 

, which provide evidence-based recommendations to support clinicians in diagnosis, monitoring, and treatment selection, fostering a more standardized and patient-centered approach.

Together, these therapies, spanning endothelin-angiotensin signaling modulation, complement inhibition, and targeted anti-inflammatory strategies, illustrate a shift toward precision medicine in rare kidney disease. 

6 New Kidney Disease Medications Approved in 2025. National Kidney Foundation. Published January 21, 2026. 

https://www.kidney.org/news-stories/6-new-kidney-disease-medications-approved-2025

Sayna Norouzi, MD, Cheung K, Skolnik E, Peleg Y. 2025 KDIGO Guideline Update for IgAN. Hcplive.com. Published January 14, 2026. Accessed February 28, 2026. https://www.hcplive.com/view/2025-kdigo-guideline-update-for-igan

Perkovic V, Barratt J, Rovin BH, et al; APPLAUSE‑IgAN Investigators. 

Alternative complement pathway inhibition with iptacopan in IgA nephropathy.

 N Engl J Med. 2025;392(6):531‑543. doi:10.1056/NEJMoa2410316. Published online 2024 Oct 25.

Kavanagh D, Bomback AS, Vivarelli M, et al. 

Oral iptacopan therapy in patients with C3 glomerulopathy: a randomized, double‑blind, placebo‑controlled, phase 3 study.

 Lancet. 2025;406(10512):1587‑1598. doi:10.1016/S0140‑6736(25)01148‑1.

Lafayette R, et al; NefIgArd Investigators. 

Efficacy and safety of a targeted‑release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2‑year results from a randomized phase 3 trial.

KDIGO IgAN and IgA Vasculitis Work Group; Rovin BH, Barratt J, Cook HT, et al. 

KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

 Kidney Int. 2025;108(4S):S1‑S71. doi:10.1016/j.kint.2025.04.004.

Novartis receives FDA accelerated approval for Fabhalta (iptacopan), the first and only complement inhibitor for reduction of proteinuria in adults with primary IgA nephropathy.

Novartis investigational atrasentan Phase III study demonstrates clinically meaningful proteinuria reduction in patients with IgA nephropathy (ALIGN).

Videos

On Rare Disease Day 2026, clinicians share their perspective on the evolving landscape for IgAN and C3G. 

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

GLP-1s Linked to Reduced Asthma Exacerbations, With Ruchi Patel, MD

Initiation of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with a significantly lower risk of 

exacerbations in non-diabetic patients with overweight and obesity, according to research presented at the 2026 

Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) 

in Philadelphia from February 27 – March 2.

 spoke with Ruchi Patel, MD, from Rutgers NJMS, on the clinical implications of these findings, including the magnitude of asthma exacerbation reduction clinicians might expect when initiating GLP-1 therapy and whether asthma specialists should take a more proactive role in discussing GLP-1 receptor agonists with primary care physicians.

“I think a lot of the primary care providers and obesity specialists [are] pretty aware of the GLP-1s already, but definitely, if the patient comes to a specialist, and it hasn't been brought up yet, it's a really good thing to bring up,” Patel said.

The study included non-diabetic patients with asthma categorized as overweight (BMI 25.00–29.99 kg/m²), obese (BMI 30.00–40.00 kg/m²), or morbidly obese (BMI ≥40.00 kg/m²). After propensity score matching, the overweight cohort included 710 patients, the obese cohort 1,515 patients, and the morbidly obese cohort 1,249 patients.

In an analysis using the TriNetX global research network, Patel and colleagues observed absolute risk reductions ranging from 12.2% to 14.6% over a 3-year follow-up period among patients who initiated a GLP-1 receptor agonist compared with matched controls without GLP-1 exposure.¹

“To translate it into more of a real world number, that's 12 to 15 less exacerbations per 100 patients that are treated with the GLP-1,” Patel said.

GLP-1 initiation in the overweight group was associated with a risk ratio (RR) of 0.748 and an absolute risk reduction of 14.6%. In the obese group, the RR was 0.790 with a 12.2% absolute risk reduction, while in the morbidly obese group, the RR was 0.780 with a 13.3% absolute risk reduction.¹

Obesity is a well-established modifier of asthma severity and control, with patients often experiencing increased symptom burden and exacerbation risk. Weight loss interventions, including bariatric surgery, have previously been associated with improvements in asthma outcomes.

However, GLP-1 receptor agonists have not been incorporated into asthma management strategies, and their potential respiratory effects remain under investigation.

In discussing the mechanism behind the observed association, Patel cautioned that the reduction in exacerbations likely reflects more than one pathway. “It’s probably a bit of both,” she said, referring to weight loss and potential anti-inflammatory effects of GLP-1 receptor agonists. “The reason why I think it's not just weight loss and it's also the anti-inflammatory effects of the GLP-1 is because even in our overweight category, where I would have expected a more modest weight loss, their results stayed pretty consistent compared to the other BMI category. That makes me think it's not just weight loss, but also the anti-inflammatory effects of the GLP-1.”

Patel R, et al. GLP-1 receptor agonists associated with reduced asthma exacerbation in patients without diabetes. Presented at American Academy of Allergy, Asthma & Immunology Annual Meeting; February 27–March 2, 2026 in Philadelphia, PA. Published in online supplement of 

https://www.aaaai.org/about/news/news/2026/glp1

Mawlichanów M, Tatara P, Kwiatkowski A, Różańska-Walędziak A, Walędziak M. Bariatric Surgery in Asthma: A Narrative Review. 

. 2024;60(5):806. Published 2024 May 14. 

Retrospective analysis presented at AAAAI 2026 found 12%–15% risk reductions in asthma exacerbations over 3 years among patients without diabetes with overweight and obesity.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

What CAFETERIA Means for Long-Term OIT Goals, with Scott Sicherer, MD

Months after topline results from the CAFETERIA study demonstrated the ability to instill high levels of tolerance in children with high-threshold peanut allergy, questions remain about how its findings fit within traditional oral immunotherapy (OIT) goals and how it highlights the distinction between desensitization and sustained unresponsiveness.

The CAFETERIA study was highlighted in a session given by Scott H. Sicherer, MD, Director of the Elliot and Roslyn Jaffe Food Allergy Institute and the Elliot and Roslyn Jaffe Professor of Pediatric Allergy and Immunology at the Icahn School of Medicine at Mount Sinai, at the 

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania.

sat down with Sicherer to discuss how clinicians should interpret the study’s results in real-world practice. He noted that terms like “remission” and “sustained unresponsiveness” are often used loosely, but in research they are highly protocol-specific. In many OIT trials, sustained unresponsiveness is defined by a relatively short avoidance period of often 6 weeks before re-challenge. In CAFETERIA, the team sought to mirror a more realistic scenario. After children demonstrated the ability to tolerate the equivalent of a peanut butter sandwich, they were asked to incorporate peanut more naturally into their diets for 16 weeks, consuming modest amounts weekly rather than adhering to a strict daily regimen. Only after that period were they instructed to completely avoid peanut for eight weeks before undergoing a final oral food challenge.

Most participants maintained tolerance after that extended, real-world–informed approach. Still, Sicherer is cautious about framing the results as a “cure.” In practice, he continues to counsel families that ongoing ingestion is important. Even if 1 to 2 tablespoons per week appears sufficient to maintain benefit, prolonged avoidance could allow clinical reactivity to return. For that reason, he advises continued dietary inclusion and routine follow-up rather than declaring the allergy resolved.

While CAFETERIA was a single-site study can not be generalized across food allergies, Sicherer believes the core principle of the study, that individuals with lower baseline IgE levels and higher initial tolerance thresholds may respond more readily to low-intensity OIT, likely extends beyond peanut. The concept may be applicable to other common allergens such as milk, egg, or tree nuts and would benefit from broader replication. Whether larger, multi-center trials will test that hypothesis remains to be seen, but the phenotype-driven approach introduced by CAFETERIA may signal a broader evolution in food allergy management.

“There's nothing so special about peanut. In fact, it might be that peanut would have been a harder case to approach. So would this apply to egg or milk or or other nuts and just other foods in general? I think the answer is yes. But are the studies going to be done? We'll wait and see,” Sicherer said.

Sicherer SH, Bunyavanich S, Berin MC, et al. Peanut Oral Immunotherapy in Children with High-Threshold Peanut Allergy. 

. Published online February 10, 2025. doi: 10.1056/evidoa2400306

Sicherer S. FAED Presents: The Potential for Tolerance After Oral Immunotherapy in High-Threshold Patients: The CAFETERIA Study. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Session 1705.

Sicherer discussed how the study might shift clinical thinking in pediatric food allergy. 

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

The United States (US) Food and Drug Administration (FDA) has granted accelerated approval to navepegritide (YUVIWEL), a once-weekly C-type natriuretic peptide (CNP) analog, to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses. The decision was based on improvements in annualized growth velocity (AGV) from 3 phase 3 trials, with continued approval contingent on confirmatory evidence of clinical benefit.

“The approval of once-weekly YUVIWEL is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” Carlos A. Bacino, MD, FACMG, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital, said in Ascendis Pharma’s statement.

 “My goal is to help children and parents develop care plans tailored to their individual needs and objectives, and I look forward to adding YUVIWEL to my discussions with them.”

Achondroplasia, the most common form of disproportionate short stature, is caused by activating variants in fibroblast growth factor receptor 3 (FGFR3), resulting in impaired endochondral ossification. Beyond short stature, affected individuals face increased risks of foramen magnum stenosis, spinal stenosis, sleep-disordered breathing, and other neurologic and orthopedic complications.

 Therapeutic strategies have focused on modulating the overactive FGFR3 pathway, including use of CNP analogs to counterbalance signaling at the growth plate.

“Little People of America, the largest national advocacy and support organization for people with dwarfism, is committed to ensuring that the voices of people with dwarfism remain central in conversations about research and medical options such as YUVIWEL,” said the Board of Directors of Little People of America.

 “We champion dwarf and disability pride, advocate for inclusion and respect, and foster open dialogue across diverse perspectives. Our goal is to empower individuals and families to make healthcare decisions that reflect their own values and experiences, while pushing for research efforts and new treatment options such as this that could have the potential to support outcomes that truly matter to our community.”

The FDA’s decision was supported by 3 randomized, double-blind, placebo-controlled trials of navepegritide, including the pivotal phase 3 ApproaCH study, as well as open-label extension data of up to 3 years. Detailed results from the phase 3 trial have been published in 

 In that study, once-weekly navepegritide significantly increased AGV compared with placebo in children with achondroplasia. The most commonly reported adverse events (AEs) were injection-site reactions and mild, transient hypotension; serious AEs were infrequent.

Navepegritide was approved under the accelerated approval pathway based on increased AGV as a surrogate outcome reasonably likely to predict clinical benefit. Confirmatory trials will be required to verify longer-term functional outcomes, such as adult height, complication rates, or quality-of-life measures.

“We are confident in YUVIWEL’s potential to transform the treatment of achondroplasia and are deeply grateful to patients, clinicians, and advocates for their many contributions to this important milestone,” Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma, added.

 “We have listened to advocacy groups for people with dwarfism to ensure we address what the community actually cares about. This reflects our ongoing commitment to pursue outcomes that patient communities have told us are important to them, and gives the achondroplasia community a new way to look at the promise of pharmacological treatment options.”

 C-type natriuretic peptide analog (prodrug)

 Increase linear growth in children ≥2 years with achondroplasia and open epiphyses

 FDA accelerated approval (February 2026)

 Increased annualized growth velocity vs placebo

 Injection-site reactions; transient hypotension

CNP is an endogenous peptide that promotes endochondral bone growth by antagonizing the MAPK pathway downstream of FGFR3. By enhancing CNP signaling, navepegritide aims to offset the constitutive FGFR3 activation characteristic of achondroplasia. As with other CNP analogs, blood pressure monitoring is recommended given the peptide’s vasodilatory properties.

Until 2021, management of achondroplasia was largely supportive and surgical. In November 2021, the FDA approved vosoritide, a daily CNP analog, to increase growth velocity in children with open growth plates.

 Vosoritide demonstrated an approximate 1.6 cm/year increase in AGV compared with placebo in a phase 3 trial.

Navepegritide represents an alternative CNP-based approach, designed as a prodrug to provide sustained systemic CNP exposure over a weekly dosing interval. Whether once-weekly dosing translates into differences in adherence, tolerability, or long-term outcomes compared with daily therapy remains to be established in comparative studies.

As with vosoritide, the clinical relevance of increased childhood growth velocity to long-term morbidity—such as need for orthopedic procedures, neurologic complications, or adult functional status—remains under investigation. 

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older. News release. Ascendis Pharma. February 27, 2026. 

https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children

Savarirayan R, McDonnell C, Bacino CA, et al. Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial. 

. 2026;180(1):18-25. doi:10.1001/jamapediatrics.2025.4771

US Food and Drug Administration. FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism. News release. November 19, 2021. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-improve-growth-children-most-common-form-dwarfism

Savarirayan R, Wilcox WR, Harmatz P, et al. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. 

. 2024;8(1):40-50. doi:10.1016/S2352-4642(23)00265-1

Articles

FDA accelerated approval was granted to once-weekly navepegritide (YUVIWEL), a C-type natriuretic peptide analog, for children ≥2 years with achondroplasia and open epiphyses to increase linear growth. Approval was supported by three randomized, double-blind, placebo-controlled phase 3 trials, including APPROACH, plus open-label extensions up to three years, demonstrating increased annualized growth velocity. Mechanistically, augmented CNP signaling counterbalances FGFR3-driven MAPK overactivity at the growth plate. Common adverse events included injection-site reactions and mild, transient hypotension. Continued authorization requires confirmatory evidence linking growth gains to durable clinical benefit and patient-relevant outcomes.

Navepegritide, to be marketed as YUVIWEL, is the only FDA-approved treatment providing continuous CNP exposure over its weekly dosing interval.

FDA News

Family Medicine

Family Medicine condition center page, resources on the topics of medical news and expert insight into family care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on Family medicine research, treatment, and drug development.

FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older

an internal medicine and pediatrics-trained allergist practicing in Mobile, Alabama.

What to Expect for Sleep Improvement With Tapinarof in AD, With Druhan Howell, MD

Counseling families about treatment timelines in pediatric 

often centers on when meaningful itch relief can be expected, but emerging data on tapinarof cream now allows clinicians to incorporate anticipatory guidance around sleep improvement into those early discussions as well.

At the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in Philadelphia from February 27 - March 2, HCPLive spoke with Druhan Howell, MD, an allergist from Mobile, Alabama, on a recent pooled analysis of ADORING 1 and ADORING 2 examining sleep outcomes of once-daily tapinarof for 8 weeks in pediatric patients with moderate to severe AD.

The analysis showed that once daily tapinarof cream 1% (VTAMA), an US Food & Drug Administration (FDA)-approved nonsteroidal topical aryl hydrocarbon receptor agonist for AD, was associated with early and sustained improvements in sleep-related outcomes in children aged 2 – 17 years.

Investigators observed sleep improvements as early as 1 week. By week 8, children treated with tapinarof demonstrated greater mean improvements in POEM and DFI scores compared with those who received vehicle. This was observed across age groups 2 – 6 years (

For Howell, this alignment between itch reduction and sleep improvement provides a practical framework for expectation-setting. Families frequently present after prolonged periods of nocturnal scratching and fragmented sleep. Being able to counsel that both itch and sleep may begin to improve within the first week offers a tangible and time-bound treatment goal. She emphasized that sustained improvement through 8 weeks, along with a safety and tolerability profile consistent with earlier analyses, supports incorporating sleep into routine counseling.

Howell said the findings match up to what she sees in clinical practice, with tapinarof cream improving sleep.

“I've had patients who we are seeing, and they come back, and we're talking about how nice it is now that the kids are not up all night, scratching and itching, waking parents up, waking other siblings up that they share bedrooms with,” Howell said. “Those discussions [of sleep improvement] were already happening on the side in my clinic, but now I have some meaningful data that is representative of that clinical impact that I was already seeing.”

Reported disclosures for Howell include Organon, Dermavant Sciences, Inc., AstraZeneca Pharmaceuticals LP, Actelion Pharmaceuticals US, Inc., GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., CSL Behring, Takeda Pharmaceuticals U.S.A., Inc., Blueprint Medicines Corporation, Amgen Inc., Philips North America LLC, Pulmonx Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Grifols USA, LLC, Baxter Healthcare, Vifor Pharma, Inc., Mylan Specialty L.P., and more.

Boguniewicz M, Eichenfield LF, Kwong P, Hebert A. Improvement in sleep and family impact for pediatric patients down to 2 years of age with atopic dermatitis treated with tapinarof cream 1% once daily in two pivotal phase 3 trials. J Allergy Clin Immunol. 2026;157(2). 

https://www.jacionline.org/article/S0091-6749(25)XXXX-X/fulltext

Howell D. Tapinarof Cream 1% Improves Sleep in Atopic Dermatitis, With Druhan Howell, MD. HCPLive. Published on February 27, 2026. Accessed on February 27, 2026. 

https://www.hcplive.com/view/tapinarof-cream-1-improves-sleep-atopic-dermatitis-druhan-howell-md

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

UChicago GI faculty bring expert endoscopy and IBD care closer to you, with seamless hospital follow-up and cutting-edge clinical trials.

Expanding Access, Advancing Science- How the University of Chicago Is Redefining IBD Care Across Chicagoland

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The long-acting growth hormone is now indicated for children aged 2.5 years and older with Idiopathic Short Stature, born Small for Gestational Age, or Noonan Syndrome.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

FDA Approves 3 New Pediatric Indications for Once-Weekly Somapacitan-beco (Sogroya)

Post hoc pooled data from ADORING 1 and 2 demonstrate statistically significant improvements in patient and family sleep scores in children aged 2–17 years

Tapinarof Cream 1% Improves Sleep in Atopic Dermatitis, With Druhan Howell, MD

Sicherer discussed how findings from CAFETERIA may inform treatment decisions for children with high-threshold allergy.

CAFETERIA: Expanding Treatment Pathways for High-Threshold Peanut Allergy, with Scott Sicherer, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

These new data from the OLYMPIA open-label extension study highlight long-term safety and efficacy findings on nemolizumab (Nemluvio).

Nemolizumab Shows Long-Term Efficacy in Prurigo Nodularis for Up to 3 Years

Mohammad Anadani, MD, is the chief of neuroendovascular services for Intent Medical Group at the Endeavor Health Advanced Neurosciences Center.

Anadani discusses a recent study highlighting the myriad contributing factors in the steadily increasing risk of maternal stroke across the country.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Pregnancy-Related Maternal Stroke Increasing Across US, With Mohammad Anadani, MD

Adrian Brown, PhD, NIHR Advanced Fellow and Associate Professor in Nutrition and Dietetics at University College London and programme co-lead of the MSc Dietetics (Pre-registration) course

Brown discusses a destigmatised future of obesity management in patients with kidney failure. 


Chronic Kidney Disease

Destigmatizing Obesity in Kidney Failure Patients Seeking Transplants, With Adrian Brown, PhD

Bhatt discusses a recent study from GSK highlighting AREXVY’s efficacy in lowering major adverse cardiovascular events.

RSV Vaccine Demonstrates Cardioprotective Effects, Reduces MACE and Hospitalizations, With Deepak Bhatt, MD, MPH

Ross Milner, MD, discusses rising vascular complexity, advanced imaging and AI, and the team-based strategies driving durable aortic and limb salvage outcomes.

Atherosclerotic Cardiovascular Disease

Expanding the Toolbox for Complex Aorta and Limb Salvage

Joselle Cook, MD, MBBS, is a hematologist and oncologist, specializing in Myeloma, Amyloid and Plasma cell disorders at the Mayo Clinic in Rochester Minnesota.

Panelist member explains new ASH guidelines aim to improve early diagnosis of AL amyloidosis with blood, urine, and biopsy testing.


Latest News

Rare Disease Day 2026: Kidney Diseases Enter Optimistic Therapeutic Era

GLP-1s Linked to Reduced Asthma Exacerbations, With Ruchi Patel, MD

What CAFETERIA Means for Long-Term OIT Goals, with Scott Sicherer, MD

FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older

What to Expect for Sleep Improvement With Tapinarof in AD, With Druhan Howell, MD